Longeveron Inc (NASDAQ: LGVN) is a clinical-stage cell therapy company developing allogeneic biologics for serious diseases with unmet medical needs. The company has no approved commercial products as of the 10-K filed March 17, 2026, and generates minimal revenue from contract development and manufacturing services rather than product sales. Its lead investigational candidate, laromestrocel, holds FDA RMAT Designation and Fast Track Designation for mild Alzheimer's disease, and an IND for pediatric dilated cardiomyopathy became effective in July 2025. Longeveron operates a cGMP-compliant manufacturing facility in Miami, Florida, which serves as both its clinical supply source and corporate headquarters. The company was founded under an exclusive license from the University of Miami, first executed in November 2014. It has never commercialized an investigational product and funds operations primarily through equity raises. Contract manufacturing revenue, derived from a fee-for-service agreement with a third-party biotechnology company entered in February 2024, substantially decreased during 2025 with no significant future revenue anticipated under that agreement.

Revenue model

Fee-for-service contract development and manufacturing agreements with third parties, billed at fixed monthly fees per manufacturing suite. Revenue is recognized over time as services are provided. No product revenue as of the filing date. The primary contract, entered February 2024, saw activity substantially decrease during 2025.

Products and services

Laromestrocel: investigational allogeneic cell therapy in clinical development for mild Alzheimer's disease (RMAT Designation, Fast Track Designation) and pediatric dilated cardiomyopathy (IND effective July 2025). Contract development and manufacturing services offered to third-party biotechnology companies on a fee-for-service basis.

Customers and end markets

End markets are patients with mild Alzheimer's disease and pediatric dilated cardiomyopathy. The sole disclosed contract manufacturing customer is an unnamed third-party biotechnology company. No commercial product customers exist as of the filing date.

Value-chain role

Longeveron occupies an early-stage drug developer and cell therapy manufacturer role. It holds an exclusive license from the University of Miami, conducts its own clinical trials, and operates an internal cGMP manufacturing facility in Miami, Florida for clinical supply. Commercial-scale production for any approved product is intended to be outsourced to a CDMO.

Geographic exposure

Operations are based in Miami, Florida, where the company maintains its manufacturing facility and corporate headquarters. No international operations are disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-17

Industry: Pharmaceutical Preparations Peers: Adverum Biotechnologies, Inc. Axcella Health Inc. Checkpoint Therapeutics, Inc. Cypherpunk Technologies Inc PDS Biotechnology Corp Climb Bio Inc HCW Biologics Inc Q32 Bio Inc SPECTRUM PHARMACEUTICALS INC